Scarica l'app Stockscreener
16.91
24.98%
3.38
Dopo l'orario di chiusura:
16.91
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Stoke Therapeutics Inc Borsa (STOK) Ultime notizie
Stoke Therapeutics Reports 'Impressive' Data for Severe Epilepsy Treatment, Wedbush Says - MarketScreener
Stoke Therapeutics 2025 Q2 Earnings Net Income Cuts Loss by 8.6% - AInvest
Stoke Therapeutics Q2 Loss Narrows, Revenue Rises - 富途牛牛
Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Call Highlights: Strong Growth and Strategic ... - Yahoo Finance
Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - BioSpace
Stoke Therapeutics Impresses With Strong Results For Dravet Syndrome Drug - Finimize
Earnings call transcript: Stoke Therapeutics beats Q2 2025 expectations - Investing.com
Stoke Therapeutics shares rise 2.73% after-hours following positive Q2 results and Phase 3 trial initiation. - AInvest
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Stoke Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Stoke Therapeutics earnings beat by $0.10, revenue topped estimates - Investing.com Canada
STOKE THERAPEUTICS Earnings Results: $STOK Reports Quarterly Earnings - Quiver Quantitative
Stoke Therapeutics Q2 2025 slides: Phase 3 Dravet trial underway, ADOA program advances - Investing.com Canada
Stoke's Dravet Syndrome Treatment Shows 3-Year Durability as Pivotal Trial Begins - Stock Titan
Can Stoke Therapeutics Inc. outperform under higher oil pricesStrong Support Zone Stocks - thegnnews.com
First patient dosed in Phase III trial of zorevunersen for Dravet syndrome - Clinical Trials Arena
Stoke Therapeutics shares fall 2.74% premarket after dosing first patient in Phase 3 EMPEROR study of zorevunersen. - AInvest
Stoke Therapeutics Earnings Preview: Analyst Expectations and Market Sentiments - AInvest
A Look Ahead: Stoke Therapeutics's Earnings Forecast - 富途牛牛
Stoke Therapeutics Inc (STOK) Q2 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Biogen and Stoke Therapeutics Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome - Ariva
First Dravet syndrome patient dosed in Phase 3 trial of zorevunersen - Investing.com Canada
Biogen, Stoke dose first patient in phase 3 Dravet syndrome trial By Investing.com - Investing.com South Africa
Biogen, Stoke dose first patient in phase 3 Dravet syndrome trial - Investing.com
Biogen and Stoke Therapeutics Announce First Patient Dosed - GlobeNewswire
Institutional scanner results for Stoke Therapeutics Inc.Asset Growth Pattern and Return Summary - Newser
Building trade automation scripts for Stoke Therapeutics Inc.Free Fundamental Growth Stock Analysis - Newser
Multi asset correlation models including Stoke Therapeutics Inc.Free Trend Following Strategy With Stop Loss - Newser
Can momentum traders help lift Stoke Therapeutics Inc.Free Wealth Building Stock Market Ideas - Newser
Will Stoke Therapeutics Inc. bounce back from current supportLow Drawdown Stock Screener with Analysis - Newser
Stoke Therapeutics Inc. Company’s Quarterly Earnings Growth: What the Numbers SayEquity Forecast with Predictive AI Screener - Newser
Stoke Therapeutics Inc. Outperforms Peers on Volume MetricsAccurate Buy Point for Momentum Stocks Detected - beatles.ru
Stoke Therapeutics STOK 2025Q2 Earnings Preview Upside Potential on Innovative Fluorescence Applications - AInvest
Stoke Therapeutics Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
Stoke Therapeutics to Host Q2 2025 Business and Financial Update Webcast and Conference Call. - AInvest
Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates - The Globe and Mail
Stoke Therapeutics Earnings Call to Reveal Latest Progress on Revolutionary Dravet Syndrome Treatment - Stock Titan
Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference - BioSpace
Stoke Therapeutics to Showcase Dravet Syndrome RNA Treatment at Major Growth Conference - Stock Titan
Published on: 2025-08-05 00:18:53 - beatles.ru
Combining machine learning predictions for Stoke Therapeutics Inc.Predictive Short-Term Market Reversal Alerts - Newser
Stoke Therapeutics (STOK) Expected to Announce Quarterly Earnings on Wednesday - Defense World
Trendline Breach Raises Concern for Stoke Therapeutics Inc. InvestorsVerified Signal From Chart Patterns Detected - metal.it
Should I hold or sell Stoke Therapeutics Inc. stock in 2025Maximize returns with strategic portfolio planning - Jammu Links News
Is Stoke Therapeutics Inc. a growth stock or a value stockRemarkable growth - Jammu Links News
Is it the right time to buy Stoke Therapeutics Inc. stockMaximize returns with expert trading insights - Jammu Links News
How many analysts rate Stoke Therapeutics Inc. as a “Buy”Invest confidently with data-driven strategies - Jammu Links News
What analysts say about Stoke Therapeutics Inc. stockRapid return acceleration - Jammu Links News
Does Stoke Therapeutics Inc. stock perform well during market downturnsAchieve breakthrough results with expert guidance - Jammu Links News
How strong is Stoke Therapeutics Inc. company’s balance sheetMaximize your portfolio’s growth potential - Jammu Links News
How volatile is Stoke Therapeutics Inc. stock compared to the marketUnlock expert insights for smarter investing - Jammu Links News
How does Stoke Therapeutics Inc. compare to its industry peersRapid wealth accumulation - Jammu Links News
What catalysts could drive Stoke Therapeutics Inc. stock higher in 2025Double or triple returns - Jammu Links News
What drives Stoke Therapeutics Inc. stock priceDiscover investment plans that deliver results - Jammu Links News
What makes Stoke Therapeutics Inc. stock price move sharplyUnlock hidden market opportunities today - Jammu Links News
When is Stoke Therapeutics Inc. stock expected to show significant growthGet expert insights on market-moving stocks - Jammu Links News
What are Stoke Therapeutics Inc. company’s key revenue driversExpert Picks Target Finder For Consistent Profits - Jammu Links News
Analysts Estimate Stoke Therapeutics, Inc. (STOK) to Report a Decline in Earnings: What to Look Out for - MSN
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):